Adaptive Biotechnologies
NEWS
As Omicron dominates the COVID-19 landscape, scientists are urging the FDA to reconsider how the agency defines immune responses.
Shares of Adaptive are climbing this morning after the company announced a reorganization of priorities to spur future growth, including a workforce reduction of approximately 12%.
The T cell response was measured with immunoSEQ® T-MAP™ COVID, a clinical test developed by Adaptive Biotechnologies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
It’s the first time in several weeks that the number of non-COVID-19-related clinical trial stories outnumber the COVID-19-related stories. It’s also a hopeful sign that some of the rest of the clinical trials are getting back on track. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
There were plenty of clinical trial announcements this week. Here’s a look.
Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones.
JOBS
IN THE PRESS